SuperworthPERRIGO profit margin PRGO
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- −41.9%
- Operating margin, 12 months
- −37.7%
- Net margin on a year earlier
- −40.0 pts
- Peer median
- 11.1%
Over the twelve months to Jun 27, 2026, PERRIGO kept −41.9% of its revenue as net profit, with an operating margin of −37.7% and a gross margin of 33.3%.
Five years earlier its net margin was −8.2%.
The median for 10 large drugmakers of a similar size is 11.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −33.5% | −26.4% | 35.1% |
| FY2024 | −3.9% | 2.6% | 35.3% |
| FY2023 | −0.3% | 3.3% | 36.1% |
| FY2022 | −3.2% | 1.8% | 32.7% |
| FY2021 | −1.7% | 9.9% | 34.2% |
| FY2020 | −3.8% | 6.1% | 36.5% |
| FY2019 | 3.0% | 4.2% | 36.7% |
| FY2018 | 2.8% | 5.0% | 38.7% |
| FY2017 | 2.4% | 12.1% | 40.0% |
| FY2016 | −76.0% | −37.9% | 38.9% |
| FY2015 | 3.2% | 16.7% | 38.9% |
| FY2015 | −0.0% | 9.0% | 40.9% |
| FY2014 | 5.1% | 14.0% | 35.7% |
| FY2013 | 12.5% | n/a | 36.2% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −41.9% | −40.0 pts | −37.7% | |
| Q1 FY26 | −43.5% | −39.3 pts | −36.9% | |
| Q4 FY25 | −33.5% | −29.6 pts | −26.4% | |
| Q3 FY25 | −1.2% | +2.4 pts | 6.5% | |
| Q2 FY25 | −1.9% | +1.0 pts | 6.6% | |
| Q1 FY25 | −4.2% | −4.0 pts | 5.0% | |
| Q4 FY24 | −3.9% | −3.7 pts | 2.6% | |
| Q3 FY24 | −3.6% | −3.5 pts | −0.4% | |
| Q2 FY24 | −2.8% | −1.3 pts | −0.8% | |
| Q1 FY24 | −0.2% | +2.9 pts | 1.1% | |
| Q4 FY23 | −0.3% | +2.9 pts | 3.3% | |
| Q3 FY23 | −0.1% | +2.3 pts | 4.3% |
Against its peers
Companies in Drug Manufacturers - General nearest PERRIGO's size, closest first, today.
| Company | Profit margin |
|---|---|
| PRGOPERRIGO | −41.9% |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| NRIXNurix Therapeutics | 42.0% |
| ANIPANI Pharmaceuticals | 11.1% |
| PAHCPhibro Animal Health | 6.6% |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 2.0% |
| OGNOrganon | 3.4% |
| LQDALiquidia | 30.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| Peer median | 11.1% |
Where PERRIGO ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on PERRIGO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.